Breaking News Instant updates and real-time market news.

PTCT

PTC Therapeutics

$36.64

-0.145 (-0.39%)

, RHHBY

Roche

$0.00

(0.00%)

07:25
05/07/19
05/07
07:25
05/07/19
07:25

PTC Therapeutics announces data from Firefish and Sunfish studies

PTC Therapeutics (PTCT) announced clinical data from the studies of FIREFISH and SUNFISH demonstrating the benefit of risdiplam for the treatment of Type 1, 2 and 3 spinal muscular atrophy. Patients across all studies continue to achieve motor milestones relative to natural history. Risdiplam has been well tolerated at all doses across studies; there have been no drug related safety findings leading to withdrawal. Regulatory submissions based on Part 1 of FIREFISH and SUNFISH are planned in the second half of 2019. The data from these pivotal trials were presented at the 2019 American Academy of Neurology Annual Meeting in Philadelphia. The SMA program is a collaboration between PTC, the SMA Foundation, and Roche (RHHBY).

PTCT

PTC Therapeutics

$36.64

-0.145 (-0.39%)

RHHBY

Roche

$0.00

(0.00%)

  • 28

    May

  • 31

    May

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

PTCT PTC Therapeutics
$36.64

-0.145 (-0.39%)

10/03/18
BOFA
10/03/18
UPGRADE
BOFA
Neutral
PTC Therapeutics upgraded to Neutral from Underperform at BofA/Merrill
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
11/12/18
CANT
11/12/18
NO CHANGE
Target $61
CANT
Overweight
PTC Therapeutics price target lowered to $61 from $66 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young lowered her price target for PTC Therapeutics to $61 on expectations the company's expense run-rate will be higher from here as it invests in new programs like gene therapy. The analyst, however, still sees upside in the shares driven by her confidence in the risdiplam. She reiterates an Overweight rating on the shares.
04/11/19
BERN
04/11/19
INITIATION
Target $48
BERN
Outperform
PTC Therapeutics initiated with an Outperform at Bernstein
Bernstein analyst Vincent Chen started coverage on PTC Therapeutics (PTCT) with an Outperform rating and a $48 price target, given his positive view on the commercial potential of risdiplam in SMA. The analyst believes that there will still be a substantial market opportunity for non-gene therapy drugs after approval, and thinks risdiplam's oral dosing will be a substantial advantage over Biogen (BIIB) Spinraza's intrathecal administration. If risdiplam is safe and comparably efficacious to Spinraza, Chen forecasts potential for $2.5B in revenues by 2030.
RHHBY Roche
$0.00

(0.00%)

04/10/19
MSCO
04/10/19
DOWNGRADE
MSCO
Underweight
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Mark Purcell downgraded Novartis (NVS) to Underweight from Equal Weight and lowered his price target for the shares to 80 francs. The spinoff of Alcon will put more attention on the generics risk Novartis faces in its pharma business, Purcell tells investors in a research note. The analyst believes this generic pressure is not priced into shares of Novartis. His top pick remains Roche (RHHBY).
04/17/19
WELS
04/17/19
NO CHANGE
WELS
Wells says Ionis weakness on Roche Huntington's update a buying opportunity
04/17/19
WELS
04/17/19
NO CHANGE
WELS
Outperform
Ionis pullback on Roche update a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterated his Outperform rating on Ionis Pharmaceuticals (IONS) following an update today from partner Roche (RHHBY) on its HTT-ASO program for Huntington's disease, stating that he believes the update continues to support potential for accelerated approval filing pending efficacy data that should be updated by year end. When asked during its earnings call about the specific filing strategy of using phase 1 OLE data in comparison to the natural history data, Roche made no comment beyond reiterating that the company will get data, share data with regulators, and work on the fastest way to bring the therapy to patients, said Birchenough. The analyst, who recommends buying Ionis on weakness, added that Roche noted that the company has had initial promising discussion with regulators.
04/22/19
BMOC
04/22/19
NO CHANGE
Target $96
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $96 from $82 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (IONS) to $96 and kept his outperform rating after including the risk-adjusted royalties for HTT-Rx in his model as part of the update on its partnership with Roche (RHHBY) disclosed last month. The analyst notes that the stock price has started to reflect the company's Huntington's disease opportunity based on the "potential for an accelerated path with Phase 2 data" and believes that his HTT-Rx projections could prove to be "conservative".

TODAY'S FREE FLY STORIES

RTLR

Rattler Midstream

$0.00

(0.00%)

10:43
05/23/19
05/23
10:43
05/23/19
10:43
Syndicate
Breaking Syndicate news story on Rattler Midstream »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

XLE

Energy Select Sector SPDR

$61.29

-2.23 (-3.51%)

10:40
05/23/19
05/23
10:40
05/23/19
10:40
Options
Massive ratio put spread in Energy SPDR ETF adjust profitable position »

Massive ratio put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$24.78

-0.33 (-1.31%)

, ALKS

Alkermes

$24.44

-0.61 (-2.44%)

10:39
05/23/19
05/23
10:39
05/23/19
10:39
Conference/Events
JPMorgan biotech analysts to hold an analyst/industry conference call »

Biotech Analysts Fye,…

ACAD

Acadia

$24.78

-0.33 (-1.31%)

ALKS

Alkermes

$24.44

-0.61 (-2.44%)

ITCI

Intra-Cellular

$13.49

0.41 (3.13%)

NBIX

Neurocrine

$78.73

-1.14 (-1.43%)

SAGE

Sage Therapeutics

$173.51

-1.49 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 05

    Jun

  • 27

    Sep

IDYA

IDEAYA Biosciences

$0.00

(0.00%)

10:37
05/23/19
05/23
10:37
05/23/19
10:37
Syndicate
IDEAYA Biosciences indicated to open at $14, IPO priced at $10 »

IDEAYA Biosciences (IDYA)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CZR

Caesars

$8.96

-0.155 (-1.70%)

10:35
05/23/19
05/23
10:35
05/23/19
10:35
Options
Caesars put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
05/23/19
05/23
10:30
05/23/19
10:30
General news
EIA natural gas storage change for week ending May 17 »

Gas inventories 100 Bcf…

RTLR

Rattler Midstream

$0.00

(0.00%)

10:25
05/23/19
05/23
10:25
05/23/19
10:25
Syndicate
Breaking Syndicate news story on Rattler Midstream »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

10:25
05/23/19
05/23
10:25
05/23/19
10:25
Conference/Events
JPMorgan TMT analyst to hold an Analyst/Industry conference call »

TMT Sector Specialist…

AGR

Avangrid

$50.37

-0.04 (-0.08%)

10:23
05/23/19
05/23
10:23
05/23/19
10:23
Hot Stocks
Avangrid Renewables announces new wind contract with Dairyland »

Dairyland Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

AMX

America Movil, also tag AMOV

$14.15

-0.19 (-1.33%)

10:20
05/23/19
05/23
10:20
05/23/19
10:20
Options
Call buyer opens a notable new position in American Movil »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$0.00

(0.00%)

, FANG

Diamondback Energy

$103.16

-5.71 (-5.24%)

10:19
05/23/19
05/23
10:19
05/23/19
10:19
Syndicate
Breaking Syndicate news story on Rattler Midstream, Diamondback Energy »

Rattler Midstream…

RTLR

Rattler Midstream

$0.00

(0.00%)

FANG

Diamondback Energy

$103.16

-5.71 (-5.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 23

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
05/23/19
05/23
10:17
05/23/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
05/23/19
05/23
10:16
05/23/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUNW

Sunworks

$0.68

0.0226 (3.42%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Hot Stocks
Sunworks wins contract to build 1 MW solar project for California school »

Sunworks announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$0.00

(0.00%)

, FANG

Diamondback Energy

$102.97

-5.9 (-5.42%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Syndicate
Rattler Midstream indicated to open at $17.50, IPO priced at $17.50 »

Rattler Midstream (RTLR),…

RTLR

Rattler Midstream

$0.00

(0.00%)

FANG

Diamondback Energy

$102.97

-5.9 (-5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 23

    May

TSLA

Tesla

$197.24

5.85 (3.06%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Periodicals
Musk says Tesla produced 900 Model 3s per day this week, Reuters reports »

Tesla has produced 900…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

SBUX

Starbucks

$76.11

-1.12 (-1.45%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Options
Starbucks put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 25

    Jun

  • 09

    Jul

10:15
05/23/19
05/23
10:15
05/23/19
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

10:15
05/23/19
05/23
10:15
05/23/19
10:15
General news
Breaking General news story  »

Week of 5/17 EIA Natural…

CMG

Chipotle

$665.03

-41.02 (-5.81%)

, BLMN

Bloomin' Brands

$18.74

-1.46 (-7.23%)

10:12
05/23/19
05/23
10:12
05/23/19
10:12
On The Fly
Chipotle seen among restaurants most at risk from African swine fever pressure »

Shares of Chipotle…

CMG

Chipotle

$665.03

-41.02 (-5.81%)

BLMN

Bloomin' Brands

$18.74

-1.46 (-7.23%)

TXRH

Texas Roadhouse

$52.05

-2.96 (-5.38%)

HRL

Hormel Foods

$38.38

-1.1 (-2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 13

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 27

    Aug

  • 28

    Aug

  • 13

    Nov

ELAN

Elanco

$32.33

-0.055 (-0.17%)

, CTB

Cooper Tire

$28.35

-0.28 (-0.98%)

10:10
05/23/19
05/23
10:10
05/23/19
10:10
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

ELAN

Elanco

$32.33

-0.055 (-0.17%)

CTB

Cooper Tire

$28.35

-0.28 (-0.98%)

GT

Goodyear Tire

$14.59

-0.41 (-2.73%)

SCPL

SciPlay

$15.40

-0.06 (-0.39%)

TH

Target Hospitality

$10.74

-0.06 (-0.56%)

ALLO

Allogene Therapeutics

$28.29

-0.75 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

QCOM

Qualcomm

$66.24

-3 (-4.33%)

, CMG

Chipotle

$665.03

-41.02 (-5.81%)

10:10
05/23/19
05/23
10:10
05/23/19
10:10
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

QCOM

Qualcomm

$66.24

-3 (-4.33%)

CMG

Chipotle

$665.03

-41.02 (-5.81%)

BLMN

Bloomin' Brands

$18.73

-1.47 (-7.28%)

SSL

Sasol

$24.66

-0.95 (-3.71%)

EXPE

Expedia

$115.63

-1.14 (-0.98%)

NTAP

NetApp

$58.89

-3.69 (-5.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 04

    Jun

  • 06

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 31

    Jul

TGT

Target

$77.90

0.4 (0.52%)

, PM

Philip Morris

$85.84

0.38 (0.44%)

10:10
05/23/19
05/23
10:10
05/23/19
10:10
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

TGT

Target

$77.90

0.4 (0.52%)

PM

Philip Morris

$85.84

0.38 (0.44%)

BKNG

Booking Holdings

$1,726.43

-19.07 (-1.09%)

VRTX

Vertex

$171.22

-1.15 (-0.67%)

RACE

Ferrari

$141.66

-1.22 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

10:10
05/23/19
05/23
10:10
05/23/19
10:10
General news
U.S. new home sales dropped 6.9% to 673k in April »

U.S. new home sales…

VRNT

Verint

$56.09

-5.12 (-8.36%)

10:07
05/23/19
05/23
10:07
05/23/19
10:07
Hot Stocks
Verint named Strong Sell at Spruce Point as M&A 'obscures' organic growth »

Shares of Verint (VRNT)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 20

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.